期刊文献+

Iressa抑制胃癌SGC-7901细胞生长的研究

Experimental study on iressa inhibits the proliferation of gastric cancer SGC-7901 cells
下载PDF
导出
摘要 目的:探讨iressa对胃癌SGC.7901细胞增殖,细胞周期和细胞凋亡的影响。方法:用四氮甲唑蓝(MTT)法检测不同浓度iressa对胃癌SGC-7901细胞增殖的影响;用流式细胞仪检测不同浓度iressa对胃癌SGC-7901细胞周期分布和细胞凋亡的影响。结果:在5~20μmol/L浓度范围内,iressa对SGC-7901的生长具有明显的抑制作用,并呈时间和剂量依赖性。10μmol/L和20uol/L的iressa可以导致SGC-7901细胞G1期阻滞,并引起细胞凋亡。结论:Iressa可改变SGC-7901细胞周期分布,诱导细胞凋亡,从而抑制细胞增殖。 Objectives :To investigate the effect of iressa on the proliferation,cell cycle and apoptosis of human gastric cancer SGC-7901 ceils. Methods:The proliferation inhibition of SGC-790 1 cells exposed to different concentration of iressa was observed by MTT assay. The cell cycle and apoptosis of SGC-7901 cells exposed to different concentration of iressa was analyzed by flowcytometry. Results:Within the rang of 5-20 umol/L,iressa obviously inhibited the proliferation of SGC-790 1 cells in a time--and dose--dependent manner. 10umol/L and20 umol/L iressa caused SGC-790 1 cells to undergo G1 arrest and induced apoptosis. Conclusion: Iressa could inhibited SGC-7901 cells proliferation,caused G1 arrest and induced apoptosis.
出处 《陕西医学杂志》 CAS 北大核心 2008年第4期459-461,共3页 Shaanxi Medical Journal
基金 陕西省攻关项目[2006K09-G6-(1)]
关键词 胃肿瘤/免疫学 苯胺化合物/药理学 细胞凋亡/免疫学 细胞周期 细胞分裂 @SGC-7901细胞 受体 表皮生长因子 Stomach neoplasms/immunology Aniline compounds/pharmacology Apoptosis/immunology Cell cycle Cell division GSGC-7901ceu Receptor,epidermol growth factorr
  • 相关文献

参考文献12

  • 1Fruehauf J. EGFR funxtion and detection in cancer therary. Ther Oncol, 2006,5 (3) : 231-46.
  • 2Normanno N, De- Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR)signaling in cancer. Gene,2006,366(1) :2-16.
  • 3Barker AJ,Gibson KH,Gnmdy W,et al. Studies leading to the identification ofZD 1 83 9(IRES SA):an or-ly active, selective epidermal growth factor receptortyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett, 2001,11 (14) : 1911-1914.
  • 4孙秀娣,牧人,周有尚,戴旭东,张思维,皇甫小梅,孙杰,李连弟,鲁凤珠,乔友林.中国胃癌死亡率20年变化情况分析及其发展趋势预测[J].中华肿瘤杂志,2004,26(1):4-9. 被引量:701
  • 5Hirata A, Hosoi F, Miyagawa M, et al. HER2 overexpression increasessensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 ,- heterodimer formation in lung cancer cells. Cancer Res, 2005,65 (10) : 4253-4260.
  • 6Hara F, Aoe M, Doihara H, et al. Antitumor effect of gefitinib Iressa onesophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett, 2005, 226 (1) :37-47.
  • 7Nakamura Y , Oka M ,Soda H, et a 1. Gefitinib ("Iressa", ZDI 839),an epidermalgrowth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistanceprotein/ABCG2-mediated drug resistance. Cancer Res, 2005,65(4) : 1541-1546.
  • 8Baselga J,Rischin D,Ranson M,et al. Phase I safety, pharmacokinetic,andpharmacodynamic trial of ZD 1 83 9, a selective oral epidermal growth factor receptortyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol, 2002,20 (21) : 4292-4302.
  • 9Cohen MH,Williams GA,Sridhara R,et al. FDA drug approval sunmary : gefitinib ( ZD1839 ) (Iressa) tablets. Oneologist, 2003,8 (4) : 303-306.
  • 10Frampton JE, Easthope SE. Spotlight on - efitinib in non-small-cell lung cancer. Am J Pharmacogenomics, 2005,5(2):133-136.

二级参考文献9

共引文献700

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部